Thyroid Carcinoma Warning
The FDA prescribing information for tirzepatide (Mounjaro) includes a black box warning for risk of thyroid C-cell tumours, including medullary thyroid carcinoma (MTC), as a class effect shared with all GLP-1 receptor agonists. The basis is rodent studies: in a 2-year rat carcinogenicity study, tirzepatide caused dose-dependent and duration-dependent increases in thyroid C-cell adenomas and carcinomas at clinically relevant plasma exposures. Tirzepatide is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
Human evidence strongly does NOT confirm this risk. Three lines of human evidence are reassuring:
-
FAERS pharmacovigilance (PMID 39141075): In a comprehensive analysis of the FDA Adverse Event Reporting System, tirzepatide’s safety profile was similar to GLP-1 RAs, with no significantly increased risk of medullary thyroid cancer compared to GLP-1 RAs, insulin, or SGLT2i. Among 20,000–31,000 tirzepatide-exposed patients with adverse events reported, only 20–37 thyroid cancer cases were found — a very small number over the period analysed, and not significantly elevated relative to comparators.
-
Retrospective cohort study (PMC 12544941, J Endocr Soc 2025): Following propensity score matching, patients treated with tirzepatide actually demonstrated significantly lower incidence of malignant thyroid cancer compared to controls (Relative Risk 0.348, P<0.001, 95% CI 0.297–0.408). Survival analyses showed higher survival probability in the tirzepatide cohort. The authors concluded: “Despite the black box warning for thyroid carcinoma with tirzepatide, the findings fail to prove such an association.”
-
GLP-1 RA class precedent: The same rodent-based boxed warning has existed for GLP-1 RAs (liraglutide, semaglutide, dulaglutide) since 2010. Over 15+ years of real-world use with millions of patients, no epidemiological signal for human MTC has emerged — strongly suggesting this is a rodent-specific physiological response that does not translate to humans.
Practical implications: The boxed warning and contraindication in MTC/MEN2 history should be respected — it represents appropriate regulatory caution given unresolved uncertainty. However, for patients without MTC/MEN2 history, prescribers and patients should be reassured that current human evidence does not support an elevated thyroid cancer risk from tirzepatide. Routine thyroid monitoring (beyond standard clinical practice) is not recommended in guidelines.
Ontology Thyroid Carcinoma Warning [warns_about] Tirzepatide Thyroid Carcinoma Warning [relates] GLP-1 Receptor Agonism
Evidence Summary
| Evidence source | Finding | Strength |
|---|---|---|
| Rodent 2-year study | Dose-dependent C-cell adenomas/carcinomas | Rodent data only — class effect |
| FAERS (PMID 39141075) | No significantly increased MTC risk vs GLP-1 RA | Moderate — pharmacovigilance |
| Retrospective cohort (PMC 12544941) | RR 0.348 (LOWER cancer incidence) | Moderate — observational |
| GLP-1 RA class precedent | No MTC signal in 15+ years of use | Population-level reassurance |
Practical Interpretation
- Contraindication: Personal/family history of MTC; MEN2 — apply without exception
- Other patients: Reassure; human data does not support elevated risk; routine thyroid monitoring not indicated
- Bottom line: This is almost certainly a rodent-specific C-cell physiological response; the boxed warning is regulatory caution, not a confirmed human risk
Connections
- Tirzepatide — warns_about (boxed warning; contraindicated in MTC/MEN2)
- GLP-1 Receptor Agonism — relates (shared class warning)